{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018428","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.070687+00:00","generated_at":"2026-06-02T05:59:04.915813+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Matinas BioPharma Q1 2024 net loss $5.8M; raises $10M in April, expects cash into Q2 2025","bullets":["Q1 2024 revenue $0 vs $1.1M in Q1 2023; net loss $5.8M ($0.03 per share).","Cash and equivalents $8.1M at March 31, 2024; subsequent $10M registered direct offering in April 2024.","Active partnership discussions to advance MAT2203 into Phase 3 ORALTO trial in invasive aspergillosis.","Compassionate use program has enrolled 22 patients with severe fungal infections; LNC platform abstracts at ASGCT."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018428","json":"https://secwatch.observer/filing/0001493152-24-018428.json","markdown":"https://secwatch.observer/filing/0001493152-24-018428.md","text":"https://secwatch.observer/filing/0001493152-24-018428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224018428/0001493152-24-018428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224018428/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:59:04.915813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f280642d6071b5d9adf7e73458468eb5765b082","claim":"Matinas BioPharma Holdings, Inc. reported the three months ending March 31, 2024 results: revenue no revenue for the first quarter of 2024, net income net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share, EPS $0.03 per share.","evidence_excerpt":"Matinas BioPharma Holdings, Inc . (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224018428/0001493152-24-018428-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ending March 31, 2024"},{"label":"Revenue","value":"no revenue for the first quarter of 2024"},{"label":"Net income","value":"net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share"},{"label":"EPS","value":"$0.03 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}